


INAVO122: A study of inavolisib + PH FDC SC in patients with *PIK3CA*-mutated, HER2+ locally advanced or metastatic breast cancer



INAVO122/WO44263: A Phase III, randomised, double-blind, placebo-controlled study evaluating the efficacy and safety of inavolisib + fixed-dose combination of pertuzumab + trastuzumab for subcutaneous injection (PH FDC SC) vs. placebo + PH FDC SC as maintenance therapy after first-line induction therapy in patients with *PIK3CA*-mutated, HER2+ locally advanced or metastatic breast cancer (LA/mBC)



INAVO122 is enrolling in: United States, Argentina and South Korea



Link for more information

<https://classic.clinicaltrials.gov/ct2/show/NCT05894239>



Please reach out to your local Roche/Genentech contact for more information